deltatrials
Completed PHASE1 INTERVENTIONAL 9-arm NCT01953692

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies

Sponsor: Merck Sharp & Dohme LLC

Conditions Diffuse Large B-Cell Lymphoma Follicular Lymphoma Hodgkin Lymphoma Multiple Myeloma Myelodysplastic Syndrome Non-Hodgkin Lymphoma Primary Mediastinal B-Cell Lymphoma
Interventions Lenalidomide 20 mg Lenalidomide 25 mg Pembrolizumab
Updated 20 times since 2017 Last updated: Aug 2, 2021 Started: Nov 22, 2013 Primary completion: Jun 26, 2020 Completion: Jun 26, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01953692, this PHASE1 trial focuses on Diffuse Large B-Cell Lymphoma and Follicular Lymphoma and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 20 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Dec 2021 — Jun 2022 [monthly]

    Completed PHASE1

  5. Sep 2021 — Dec 2021 [monthly]

    Completed PHASE1

▶ Show 15 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE1

  2. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE1

  3. Jul 2020 — Aug 2020 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  5. Apr 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  6. Jul 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  9. Dec 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Oct 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  11. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  12. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  13. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

  14. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.